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Basal cell adenoma (BCA) is an uncommon benign salivary gland neoplasm that includes 
isomorphic basaloid cells.  We report on a female patient with BCA that developed in the 
right parotid gland in her 50s.  The present patient demonstrated a few tumor nests in 
the fibrous capsule, and her tumor was larger than usual.  These facts made us suspect of 
malignancy.  Histopathologically, the tumor was characterized by multiple duct-like struc-
tures and tubular-trabecular masses composed of small isomorphic cells with hyperchro-
matic, round nuclei and an eosinophilic cytoplasm.  It was difficult to determine whether 
the ductal structures noted in the tumor capsule were invasive.  By immunohistochemistry, 
tumor cells of the tubular nests were positive for cytokeratin 7 and that the outer cells of 
tubular nests were positive for alpha smooth muscle actin ( SMA) and calponin.  Tumor 
cells were immuno-negative for S-100 protein and glial fibrillary acidic protein.  The Ki-67 
labeling scores of the cells were extremely low (< 1%).  We could achieve an accurate diag-
nosis of BCA by immunohistochemistry with MIB-1 and other markers.
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Salivary gland tumors are uncommon and con-
stitute 2.0% to 6.5% of all head and neck tumors 
(Leegaard and Lindeman, 1969; van der Wal et al., 
1992).  Salivary gland tumors are histologically 
diverse and include various types and subtypes. 
Therefore, the accurate diagnosis of salivary gland 
tumors is difficult in some patients.  The majority 
of salivary gland tumors are located in the parotid 
gland (Satko et al., 2000; Ito et al., 2005; Gnepp, 
2009), and benign tumors predominate over ma-
lignant tumors (Satko et al., 2000).  Pleomorphic 
adenoma is the most common salivary gland tu-
mor with an incidence ranging from 60% to 65% 
(Evenson and Cawson, 1985; Barnes et al., 2005; 
Gnepp, 2009).  On the other hand, basal cell ad-
enoma (BCA) accounts for only 1% to 3% of all 
salivary gland tumors and demonstrates a female 
predominance of 2:1 (Luna and Mackay, 1976; 
Satko et al., 2000; Vargas et al., 2002; Barnes et 
al., 2005; Gnepp, 2009).  BCA was recognized as a 
distinct disease entity in 1991 by the World Health 
Organization (Seifert and Sobin, 1991).  BCA tu-
mors have been histopathologically classified into 
solid (monomorphic), trabecular, tubular and mem-
branous types (Ellis and Auclair, 1996).  However, 
basal cells are found in various primary salivary 
gland tumors either as a component of the tumor 
or as pure basal cell neoplasms.  In this regard, the 
distinction between true BCA and other primary 
tumors mimicking the basal cell features of the 
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Fig. 1.  Contrast-enhanced magnetic resonance scans 
showing homogeneous moderate enhancement of the 
mass (arrow). Capsule-like enhancement is seen.  a: T1-
weighed image.  b: T2-weighed image.
salivary gland sometimes causes diagnostic diffi-
culties (Seifert, 1996).
 Here, we report on a female patient with BCA 
occurring in the parotid gland in her 50s.  Immu-
nohistochemistry provided useful information that 
allowed an accurate pathological diagnosis to be 
achieved in this patient.
 
 
Patient Report 
 
Clinical summary
 
A Japanese woman in her 50s was admitted to the 
Clinic of Otorhinolaryngology at San-in Rosai Hos-
pital in 2009 due to a painless swelling in her right 
parotid gland.  A physical examination revealed a 
hard-circumscribed nodule of 4 cm in diameter. 
The lesion was first noticed in 2001 and had gradu-
ally enlarged without pain.  Computed tomography 
showed a round, well-circumscribed heterogeneous 
mass measuring 3.6 × 4.3 cm in the right parotid 
gland.  No calcification or cystic component was 
seen in the tumor.  Neck magnetic resonance imag-
ing also revealed a heterogeneous, well-demarcated 
mass in the right parotid gland.  On a T1-weighted 
image, the tumor was heterogeneously isointense to 
muscle (Fig. 1a).  On a T2-weighted image, the tu-
mor demonstrated a heterogeneous moderate inten-
sity.  The signal intensity of the tumor on the T2-
weighted image was higher than that of the muscle 
(Fig. 1b). 
 Initially, her disease was clinically suspected 
as pleomorphic adenoma.  However, the probability 
of malignancy could not be ruled out so the patient 
underwent surgery.  There has been no recurrence 
for 7 months after surgery.
 
Pathological findings
 
Histopathologic examination revealed that the tu-
mor, which was encapsulated with fibrous tissue, 
was characterized by multiple duct-like structures 
or solid and trabecular masses composed of small 
isomorphic cells with hyperchromatic, round nuclei 
and an eosinophilic cytoplasm (Figs. 2a and b). 
There was no cartilage formation, mucous stroma 
or necrosis in the tumor.  The tubular portion of the 
tumor demonstrated a two-layered ductal structure. 
Mitotic figures were extremely rare (× 400/high 
power field).  Nuclear atypia and mitotic figures 
were not prominent.  In some sections, there were 
tumor cells in the wall of the capsule (Fig. 2c).  
 An immunohistochemical examination 
showed that the inner cells of the tubular com-
ponents were positive for cytokeratin (CK) 7 and 
negative for alpha smooth muscle actin ( SMA) 
and calponin (Figs. 3a and b).  On the contrary, the 
outer cells were negative for CK7 and positive for 
SMA and calponin.  Tumor cells were immuno-
ab
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negative for S-100 protein and glial fibrillary acidic 
protein (GFAP).  The stromal cells showed immu-
noreactivity for SMA, but not for S-100 protein or 
glial fibrillary acidic protein. In addition, the fre-
quency of Ki-67 positive tumor cells was extremely 
low, being less than 1%. From these findings, the 
tumor was diagnosed as a tubular-trabecular BCA.
 
 
Discussion
 
BCA is a rare, benign epithelial neoplasm of the 
salivary gland.  According to the literature, malig-
Fig. 2.  Histopathology of the basal cell adenoma (hema-
toxylin and eosin stain).  
  a:  The tumor cells demonstrate a tubular structure. 
Bar = 50 μm.
b:  Trabecular tumor cells and tumor cell nest forma-
tion.  Bar = 50 μm.
c:  Trabecular tumor cell nests are noted in the fibrous 
capsule of the tumor, mimicking infiltration.  Bar = 
100 μm.
Fig. 3.  Immunohistochemistry of the basal cell adenoma. 
 a:  The tumor cells show immunoreactivity for cytok-
eratin 7.  Bar = 50 μm.
b:  Alpha smooth muscle actin immunoreactivity is not-
ed in the outermost layer of the tubular type tumor 
cells.  Bar = 50 μm.
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nant transformation occurs in 4.3% of BCA (Nagao 
et al., 1997).  BCA frequently occurs in people of 
over 50 years of age as a unilateral tumor with a 
well-circumscribed round or oval appearance.  A 
painless, slowly enlarging mass is the most com-
mon clinical symptom (Nagao et al., 1982; Jang et 
al., 2004).  BCA tumors are usually smaller than 3 
cm.  In the present patient, the site of occurrence, 
past history, age and sex were compatible with 
those written in previous reports, but the tumor size 
was not compatible.  Microscopically, the tumor 
was histopathologically classified as BCA of the 
tubular-trabecular type. 
 The cellular type of pleomorphic adenoma is 
difficult to distinguish from BCA; however, myx-
oid or cartilage formation characteristic of pleo-
morphic adenoma was not observed in the present 
patient (Ellis and Auclair, 1996; Minicucci et al., 
2008).  In addition, immunohistochemical staining 
of the tumor cells was negative for S-100 protein 
and GFAP.  Previous reports have shown that the 
outer tumor cells in pleomorphic adenoma exhibit 
a very heterogeneous distribution or the simultane-
ous presence of S-100 protein and GFAP (Mori et 
al., 1990; Ogawa et al., 1990; Shida et al., 2005).
 Basal cell adenocarcinoma shares common 
clinical and histological similarities with BCA 
(Klijanienko et al., 1999; Machado de Sousa et 
al., 2001).  Cytology differences, infiltration and 
perineural invasion help distinguish basal cell ade-
nocarcinoma from BCA.  The present patient dem-
onstrated a few tumor nests or glands in the fibrous 
capsule.  However, nuclear atypia and mitotic fig-
ures were not prominent.  Moreover, no necrosis or 
hemorrhaging was observed.  We considered that 
tumor cells in the capsule were not of the invasive 
origin but a part or component of fibrous tissues. 
 It is difficult to differentiate between BCA 
with a two-layered tubular structure and the tubular 
type of adenoid cystic carcinoma because atypical 
tumor cells are relatively scarce in both types of 
tumor.  The Ki-67 labeling index is a useful marker 
of cell proliferation (Murakami et al., 1992; Nagao 
et al., 1998).  The Ki-67 labeling indices of adenoid 
cystic carcinoma have been reported to range from 
13.6% to 34.7%.  On the other hand, we found a 
Ki-67 labeling index of less than 1% in the present 
patient.
 We present a patient with BCA classified as a 
rare benign tumor that was difficult to differenti-
ate from other tumors with a two-layered structure. 
We emphasize the importance of immunohis-
tochemistry for obtaining an accurate diagnosis of 
BCA, particularly because BCA has the potential 
to be malignant.
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